About the Featured Technology
Since 1973, LB has been traditionally used as an oral contraceptive. Prior attempts to produce an injectable version of LB in the 1980s were not successful because of problems with chemical aggregation of the drug product, which negatively affected stability and effectiveness.
Current commercially available (non-LB) injectable contraceptives require a medical professional to administer the injection. These injectable contraceptives are also associated with serious adverse side effects, such as: blood clots (i.e., venous thromboembolism (VTE)), decrease bone density, and less serious side effects such as: weight gain and moodiness.
Therefore, there is a need for a safer and more effective injectable contraceptive. This new LB injectable formulation satisfies this need.
The NICHD seeks licensing and/or co-development partners for this technology.